O'Reilly EM - Search Results

1

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. Witkiewicz AK, et al. Cell Rep. 2016 Aug 16;16(7):2017-31. doi: 10.1016/j.celrep.2016.07.023. Epub 2016 Aug 4. Cell Rep. 2016. PMID: 27498862 Free PMC article.

2

Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.

Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM. Duffy A, et al. J Surg Oncol. 2009 Jul 1;100(1):8-12. doi: 10.1002/jso.21292. J Surg Oncol. 2009. PMID: 19384918

3

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM. Carvajal RD, et al. Pancreatology. 2009;9(4):404-9. doi: 10.1159/000187135. Epub 2009 May 19. Pancreatology. 2009. PMID: 19451750 Free PMC article. Clinical Trial.

4

New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.

Lowery MA, O'Reilly EM. Lowery MA, et al. BioDrugs. 2011 Aug 1;25(4):207-16. doi: 10.2165/11592470-000000000-00000. BioDrugs. 2011. PMID: 21815696

5

Genomics and pharmacogenomics of pancreatic adenocarcinoma.

Lowery MA, O'Reilly EM. Lowery MA, et al. Pharmacogenomics J. 2012 Feb;12(1):1-9. doi: 10.1038/tpj.2011.52. Epub 2011 Dec 20. Pharmacogenomics J. 2012. PMID: 22186617 Review.

6

Pancreatic cancer: the role of molecular markers in diagnosis and management.

Lowery MA, O'Reilly EM. Lowery MA, et al. Clin Adv Hematol Oncol. 2011 Dec;9(12):900-8. Clin Adv Hematol Oncol. 2011. PMID: 22252658 Review.

7

Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers.

O'Reilly EM, Lowery MA. O'Reilly EM, et al. Cancer J. 2012 Nov-Dec;18(6):609-13. doi: 10.1097/PPO.0b013e3182758e27. Cancer J. 2012. PMID: 23187849 Review.

8

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.

Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, Gönen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. Sadot E, et al. Ann Surg Oncol. 2015 Oct;22(11):3512-21. doi: 10.1245/s10434-015-4647-4. Epub 2015 Jun 12. Ann Surg Oncol. 2015. PMID: 26065868 Free PMC article.

9

Novel Therapeutics for Pancreatic Adenocarcinoma.

Lowery MA, O'Reilly EM. Lowery MA, et al. Hematol Oncol Clin North Am. 2015 Aug;29(4):777-87. doi: 10.1016/j.hoc.2015.04.006. Hematol Oncol Clin North Am. 2015. PMID: 26226910 Review.

10

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Knudsen ES, et al. Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15. Gastroenterology. 2016. PMID: 26385075 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters